Bivin & Associates’s Amgen AMGN Stock Holding History

Bivin & Associates’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$137K	Buy	+565	New	+$138K	0.15%	52

Other funds holding AMGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bivin & Associates's AMGN Position: Q2 2022 in Review

Bivin & Associates opened a new position in Amgen (AMGN) in Q2 2022: 565 shares worth $137K. The stake represents 0.15% of the portfolio and ranks #52 among its holdings.

2,353 funds tracked by Wall St. Rank hold AMGN as of Q2 2022.

Bivin & Associates held 565 shares of Amgen worth $137K as of Q2 2022.
Amgen was a new Bivin & Associates position in Q2 2022.
Amgen made up 0.15% of Bivin & Associates's portfolio in Q2 2022, its #52 holding.
2,353 funds tracked by Wall St. Rank held Amgen as of Q2 2022.

Based on Bivin & Associates's 13F filing for Q2 2022, filed 11 Aug 2022.